200 related articles for article (PubMed ID: 33005257)
21. Expression of STAT3, MMP-1 and TIMP-1 in gastric cancer and correlation with pathological features.
Cai QW; Li J; Li XQ; Wang JQ; Huang Y
Mol Med Rep; 2012 Jun; 5(6):1438-42. PubMed ID: 22469989
[TBL] [Abstract][Full Text] [Related]
22. Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer.
Brun JL; Cortez A; Lesieur B; Uzan S; Rouzier R; Daraï E
Oncol Rep; 2012 Apr; 27(4):1049-57. PubMed ID: 22200690
[TBL] [Abstract][Full Text] [Related]
23. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
24. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
25. Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions.
Graesslin O; Cortez A; Uzan C; Birembaut P; Quereux C; Daraï E
Int J Gynecol Cancer; 2006; 16(5):1911-7. PubMed ID: 17009991
[TBL] [Abstract][Full Text] [Related]
26. Serum MMP-8 and TIMP-1 as prognostic biomarkers in gastric cancer.
Laitinen A; Hagström J; Mustonen H; Kokkola A; Tervahartiala T; Sorsa T; Böckelman C; Haglund C
Tumour Biol; 2018 Sep; 40(9):1010428318799266. PubMed ID: 30192205
[TBL] [Abstract][Full Text] [Related]
27. Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody.
Kyllönen H; Pasanen AK; Kuittinen O; Haapasaari KM; Turpeenniemi-Hujanen T
Leuk Lymphoma; 2009 Aug; 50(8):1301-7. PubMed ID: 19811332
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
[TBL] [Abstract][Full Text] [Related]
29. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression.
Yamamoto H; Itoh F; Iku S; Adachi Y; Fukushima H; Sasaki S; Mukaiya M; Hirata K; Imai K
J Clin Oncol; 2001 Feb; 19(4):1118-27. PubMed ID: 11181677
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
[TBL] [Abstract][Full Text] [Related]
31. The influence of transforming growth factor-α, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer.
Fanelli MF; Chinen LT; Begnami MD; Costa WL; Fregnami JH; Soares FA; Montagnini AL
Histopathology; 2012 Aug; 61(2):153-61. PubMed ID: 22582975
[TBL] [Abstract][Full Text] [Related]
32. Correlation of matrix metalloproteinase-2, -9, tissue inhibitor-1 of matrix metalloproteinase and CD44 variant 6 in head and neck cancer metastasis.
Xu YP; Zhao XQ; Sommer K; Moubayed P
J Zhejiang Univ Sci; 2003; 4(4):491-501. PubMed ID: 12861629
[TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
Baker EA; Bergin FG; Leaper DJ
Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
[TBL] [Abstract][Full Text] [Related]
34. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.
Miyata Y; Kanda S; Nomata K; Hayashida Y; Kanetake H
Urology; 2004 Mar; 63(3):602-8. PubMed ID: 15028476
[TBL] [Abstract][Full Text] [Related]
35. The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.
Barabás L; Hritz I; István G; Tulassay Z; Herszényi L
Dig Dis; 2021; 39(3):217-224. PubMed ID: 32961536
[TBL] [Abstract][Full Text] [Related]
36. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer.
Mrena J; Wiksten JP; Nordling S; Kokkola A; Ristimäki A; Haglund C
J Clin Pathol; 2006 Jun; 59(6):618-23. PubMed ID: 16731602
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer.
Moser PL; Hefler L; Tempfer C; Neunteufel W; Kieback DG; Gitsch G
Anticancer Res; 1999; 19(3B):2365-7. PubMed ID: 10472357
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Yanoma S; Noguchi Y
Cancer Lett; 2000 Apr; 151(1):81-6. PubMed ID: 10766426
[TBL] [Abstract][Full Text] [Related]
39. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
40. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas.
Maeta H; Ohgi S; Terada T
Virchows Arch; 2001 Feb; 438(2):121-8. PubMed ID: 11253113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
